Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FYB206 vs Keytruda in Metastatic Non-squamous NSCLC
NCT06643117Phase 3Terminated
- Sponsor
- Formycon AG
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of FYB206 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Formycon AG. Primary endpoint: Best objective response rate at 40 weeks. Started Oct 2024; status: terminated.
02
Drugs
FYB206
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06643117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643117.